May 26, 2019 by Matthew LePoire on Uncategorized 040 – Biogen faces another headwind with Zolgensma approval Hi all, I’m back today talking about the approval of Avexis/Novartis’ gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen. Follow me on twitter @matthewlepoire http://www.breakingbiotech.com *this is not investment advice* Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Like this:Like Loading...
April 15, 2018 by Matthew LePoire on Gene Therapy, Uncategorized Novartis buys Avexis! -Novartis buys gene therapy company, Avexis for $8.7 billion http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2341482 -Spark is another gene therapy company I like, involved in hemophilia and eye-related blindness diseases http://sparktx.com/ Follow me on twitter @matthewlepoire Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Like this:Like Loading...
